Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
JT and Bayer Begin Japan PIII for HIF-PH Inhibitors, Follow Astellas and GSK
Japan Tobacco and Bayer Yakuhin have recently launched PIII trials in Japan for their hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors - a class of medicines seen as post-erythropoiesis stimulating agents (ESAs) for renal anemia treatment where Astellas Pharma and GlaxoSmithKline…
To read the full story
Related Article
- Competition Heating Up for HIF-PH Inhibitors; Astellas Expected to Be First with Filing Likely in FY2018
May 7, 2018
- Astellas Looks to Be First to Market in HIF-PH Inhibitor Space
August 8, 2017
- Development Race Heating Up for HIF-PH Inhibitors, Promising Alternative to ESAs in Renal Anemia Space?
June 22, 2017
BUSINESS
- Sumitomo Notches Record Profit on Strong North America Growth
May 14, 2026
- Takeda’s FY2025 Sales Fall 1.7% on Vyvanse Generic Erosion
May 14, 2026
- Shionogi Nets 4th Straight Year of Record Earnings on Torii Deal, HIV Royalties
May 13, 2026
- Santen’s Eylea Sales Fall 15.9% amid Re-Pricing, Biosimilar Entry
May 13, 2026
- Fuji’s Eylea Biosimilar Logs 776 Million Yen in First 3 Months
May 13, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…